Use of beta-blockers for heart failure in patients with diabetes mellitus.
Although strong evidence supports the use of beta-blockers for reducing morbidity and improving survival rates in patients with heart failure, this treatment is often underused. The presence of comorbidities, such as diabetes mellitus, is considered a precaution to the use of beta-blockers and may contribute to this underutilization. Recently completed retrospective analyses of subgroups of patients from several large, landmark heart failure trials, such as Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF), Cardiac Insufficiency Bisoprolol Study II (CIBIS-II), and the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial, have established the beneficial effects of beta-blockers in diabetic patients with heart failure. beta-blockers are as beneficial and well tolerated in patients with heart failure and diabetes as they are in those without diabetes. These observations strongly support a role for the use of beta-blockers in patients with both heart failure and diabetes.
Giles
Thomas D
TD
Cardiovascular Research Louisiana State University Health Science Center, 1542 Tulane Ave, Rm 331E, New Orleans, LA 70112, USA. tgiles@lsuhsc.edu
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use; D017298:Bisoprolol / Q000627:therapeutic use; D002227:Carbazoles / Q000627:therapeutic use; D000077261:Carvedilol; D048909:Diabetes Complications / Q000188:drug therapy* / Q000401:mortality; D003920:Diabetes Mellitus / Q000503:physiopathology*; D006333:Heart Failure / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D008790:Metoprolol / Q000627:therapeutic use; D011412:Propanolamines / Q000627:therapeutic use; D014481:United States
D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D002227:Carbazoles; D011412:Propanolamines; D000077261:Carvedilol; D008790:Metoprolol; D017298:Bisoprolol